NCT05541861: Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People |
|
|
| Active, not recruiting | 1 | 383 | US | BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg, BNT162b4 5 µg, BNT162b4 10 µg, BNT162b4 15 µg, BNT162b4 30 µg, BNT162b2 Monovalent (OMI XBB.1.5) 30 µg | BioNTech SE, Pfizer | SARS-CoV-2 Infection, COVID-19 | 11/24 | 11/24 | | |
